Acutus Competitors

Delisted . USA . 
Stock . Acutus Medical
AFIBDelisted Stock  USD 0.73  0.03  3.95%   
Acutus Medical competes with STRATA Skin, Axogen, Ainos, LENSAR, and CVRx; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Acutus Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Acutus Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Acutus Medical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.730.730.73
Details
Intrinsic
Valuation
LowRealHigh
0.680.680.80
Details

Acutus Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Acutus Medical and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Acutus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Acutus Medical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
NPCE
+ 0.9
SIEN
NPCE
+ 0.84
LNSR
LNSR
+ 0.81
SIEN
CVRX
+ 0.81
LNSR
ANIK
+ 0.71
AIMD
NPCE
+ 0.61
CVRX
  
High negative correlations   
ANIK
- 0.92
CVRX
ANIK
- 0.87
LNSR
AXDX
- 0.84
SIEN
NPCE
- 0.76
AXDX
ANIK
- 0.72
NPCE
NPCE
- 0.7
AIMD

Risk-Adjusted Indicators

There is a big difference between Acutus Stock performing well and Acutus Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Acutus Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Acutus Medical Competitive Analysis

The better you understand Acutus Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Acutus Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Acutus Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AFIB SSKN SIEN AXGN AIMD LNSR CVRX AXDX NPCE ANIK
 3.95 
 0.73 
Acutus
 0.35 
 2.88 
STRATA
 9.44 
 4.29 
Sientra
 5.41 
 16.26 
Axogen
 3.84 
 0.47 
Ainos
 12.86 
 8.69 
LENSAR
 6.52 
 12.90 
CVRx
 2.73 
 1.07 
Accelerate
 3.38 
 11.14 
Neuropace
 0.62 
 16.33 
Anika
Market Volatility
(90 Days Market Risk)
Very steady
Unstable
Very steady
Somewhat reliable
Out of control
Slightly risky
Slightly risky
Risky
Slightly risky
Not too volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Modest
Very Weak
Solid
OK
Very Weak
Good
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Dangerous
Low
Very High
Low
Below Average
Very High
Quite High
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Strong Hold
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Hold
Strong Hold
Current Ratio
5.11
1.3
1.4
4.52
0.53
3.14
16.82
4.48
9.86
6.37
Net Asset
53.96 M
42.02 M
165.42 M
196.83 M
31.84 M
69.58 M
115.23 M
31.37 M
107.65 M
270.63 M
Profit Margin
N/A
-0.25
-0.65
-0.0791
N/A
-0.34
-1.24
N/A
-0.37
-0.59
EBITDA
(13.49 M)
(3.38 M)
(43.09 M)
(13.33 M)
(8.77 M)
(8.71 M)
(43.1 M)
(49.77 M)
(22.83 M)
(11.23 M)
Operating Margin
-2.89
-0.0576
-0.48
-0.0065
-359.85
-0.092
-0.97
-2.88
-0.2
-0.64
Current Valuation
18.75 M
21.47 M
51.83 M
800.83 M
13.67 M
73.25 M
244.11 M
67.11 M
360.82 M
204.04 M
Price To Book
0.53
1.29
13.09
7.61
0.36
3.93
4.51
N/A
35.03
1.33
Retained Earnings
(599.98 M)
(238.06 M)
(694.65 M)
(281.3 M)
(37.89 M)
(111.89 M)
(477.38 M)
(668.86 M)
(503.81 M)
128.05 M
Current Asset
N/A
9.39 M
139.12 M
35.05 M
N/A
N/A
N/A
91.68 M
N/A
176.43 M
Beta
0.26
1.32
2.03
1.13
1.41
0.59
1.11
0.6
1.8
0.86
Number Of Employees
230
99
304
426
46
130
200
134
184
357
Shares Outstanding
29.72 M
4.17 M
11.96 M
44.01 M
13.84 M
11.61 M
24.26 M
25.04 M
29.85 M
14.65 M
Cash Flow From Operations
(63.61 M)
(519 K)
(11.38 M)
(5.72 M)
(4.69 M)
(9.66 M)
(39.02 M)
(40.2 M)
(19.7 M)
(1.79 M)
Total Debt
38.48 M
15.63 M
63.16 M
69.29 M
5.96 M
2.31 M
30.61 M
39.22 M
72.39 M
29.04 M
Return On Equity
-0.32
-0.63
-9.34
-0.15
-0.71
-0.38
-0.79
N/A
-2.15
-0.43
Z Score
N/A
N/A
-6.04
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.14
-0.0679
-0.21
-0.0275
-0.28
-0.0938
-0.31
-0.76
-0.15
-0.0401
Number Of Shares Shorted
553.6 K
5.75 K
1.31 M
1.09 M
161.76 K
58.38 K
1.95 M
525.03 K
249.42 K
367.51 K
Book Value Per Share
-0.03
3.62
-2.82
2.26
1.31
1.96
2.69
-1.36
0.33
12.24
Current Liabilities
N/A
4.62 M
20.52 M
3.71 M
N/A
N/A
N/A
4.45 M
N/A
17.28 M
Total Asset
53.96 M
42.02 M
165.42 M
196.83 M
31.84 M
69.58 M
115.23 M
31.37 M
107.65 M
270.63 M
Debt To Equity
0.51
0.35
9.32
0.71
5.3
0.068
0.003
2.76
1.08
0.11
Short Ratio
0.68
0.44
16.85
2.75
0.51
1.2
5.33
7.77
2.85
2.43
Target Price
0.5
16.0
2.0
18.0
N/A
11.0
18.17
1.5
16.17
26.5
Shares Owned By Institutions
23.5
60.39
17.04
84.6
1.1
42.4
71.88
17.45
82.87
91.59
Market Capitalization
2.67 M
12.05 M
2.08 M
756.5 M
5.95 M
89.43 M
293.83 M
27.55 M
344.15 M
237.7 M
Price To Earning
N/A
-0.49
-5.45
-47.07
N/A
N/A
0.19
-15.18
N/A
42.3
Price To Earnings To Growth
N/A
-0.02
-0.27
N/A
N/A
N/A
N/A
-0.55
N/A
3.47
Price To Sales
0.73
0.37
0.023
4.18
161.45
1.83
6.22
2.25
4.5
1.45
Net Income
(11.92 M)
(10.83 M)
(59.12 M)
(21.72 M)
(13.77 M)
(14.38 M)
(41.2 M)
(61.62 M)
(32.96 M)
(82.67 M)
Earnings Per Share
-0.41
-2.6
-5.26
-0.33
-2.71
-1.46
-2.69
-2.59
-0.98
-6.64
Shares Owned By Insiders
3.15
2.91
9.61
5.55
65.5
19.57
4.39
40.6
4.1
3.4
Revenue
7.16 M
33.36 M
90.3 M
159.01 M
122.11 K
42.16 M
39.3 M
12.06 M
65.42 M
166.66 M
Working Capital
27.31 M
3.37 M
18.04 M
57.57 M
1.14 M
34.81 M
104.23 M
12.43 M
76.49 M
132.25 M
Cash And Equivalents
88.97 M
10.04 M
24.99 M
58.03 M
1.75 M
25.2 M
109.98 M
36.77 M
92.41 M
87.78 M
Cash Per Share
3.14
0.29
0.4
1.37
0.09
2.29
5.34
0.45
3.72
6.01
Gross Profit
(15.55 M)
19.85 M
41.59 M
114.44 M
410.38 K
19.95 M
17.47 M
3.3 M
32.49 M
96.78 M
Day Typical Price
0.74
2.88
4.21
16.49
0.46
8.54
12.65
1.06
11.23
16.41
Accumulation Distribution
0.0519
46.28
0.12
18128.05
9065.42
6601.38
5861.76
0.0374
780.96
1320.7
Market Facilitation Index
0.04
0.0
0.51
0.0
0.0
0.0
0.0
0.04
0.0
0.0
Daily Balance Of Power
(0.75)
(0.33)
0.7255
(0.97)
0.346
0.6471
0.9518
(0.75)
(1.15)
0.2222
Period Momentum Indicator
(0.03)
(0.01)
0.37
(0.93)
0.0173
0.99
0.79
(0.03)
(0.39)
0.1
Rate Of Daily Change
0.96
1.0
1.09
0.95
1.04
1.13
1.07
0.97
0.97
1.01
Day Median Price
0.75
2.89
4.18
16.61
0.45
8.47
12.52
1.05
11.27
16.45
Price Action Indicator
(0.04)
(0.01)
0.3
(0.81)
0.0209
0.72
0.77
0.005
(0.32)
(0.07)
Coefficient Of Variation
2899.92
15034.89
656.29
997.33
48369.1
462.93
1047.67
(995.81)
666.32
(720.19)
Mean Deviation
3.77
2.62
7.84
2.54
3.8
3.34
3.62
3.21
3.67
1.77
Jensen Alpha
0.1631
0.0032
1.73
0.3312
(0.01)
0.9659
0.5795
(0.43)
0.7814
(0.63)
Total Risk Alpha
0.0179
(0.09)
1.41
0.2527
(0.16)
0.8379
0.3881
(0.56)
0.6419
(0.71)
Sortino Ratio
0.0235
(0)
0.2008
0.0856
(0)
0.2848
0.1216
N/A
0.2088
N/A
Downside Variance
41.04
12.43
73.73
15.57
26.88
11.07
19.76
N/A
13.83
N/A
Standard Deviation
5.32
3.48
11.53
3.7
5.42
4.54
6.01
4.2
5.39
4.17
Kurtosis
1.97
0.4925
2.65
3.28
2.38
2.19
10.01
0.1929
9.12
43.0
Potential Upside
7.78
5.28
25.49
5.35
8.16
8.92
9.25
8.19
9.73
3.27
Treynor Ratio
0.3826
0.0306
3.01
0.2815
0.0021
4.73
(0.84)
1.42
1.02
(0.36)
Maximum Drawdown
29.93
16.58
59.73
21.6
28.01
22.21
41.08
18.85
35.79
34.28
Variance
28.34
12.1
132.99
13.68
29.39
20.61
36.15
17.67
29.1
17.36
Market Risk Adjusted Performance
0.3926
0.0406
3.02
0.2915
0.0121
4.74
(0.83)
1.43
1.03
(0.35)
Risk Adjusted Performance
0.0358
0.013
0.13
0.0873
0.0102
0.1794
0.0843
(0.07)
0.1274
(0.10)
Skewness
(0.28)
0.214
1.09
(0.42)
1.07
1.15
2.21
0.5228
2.15
(5.87)
Semi Deviation
5.03
3.36
7.64
3.57
4.11
2.68
3.77
N/A
3.04
N/A
Information Ratio
0.0283
(0)
0.1495
0.0913
(0)
0.2087
0.0899
(0.11)
0.1439
(0.15)
Value At Risk
(8.42)
(5.25)
(15.62)
(5.50)
(8.33)
(5.28)
(8.95)
(7.11)
(6.20)
(3.39)
Expected Short fall
(4.62)
(2.73)
(10.30)
(2.68)
(5.71)
(3.97)
(4.24)
N/A
(4.39)
N/A
Downside Deviation
6.41
3.53
8.59
3.95
5.18
3.33
4.45
N/A
3.72
N/A
Semi Variance
25.32
11.27
58.43
12.75
16.87
7.18
14.25
N/A
9.25
N/A

Acutus Medical Competition Performance Charts

Five steps to successful analysis of Acutus Medical Competition

Acutus Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Acutus Medical in relation to its competition. Acutus Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Acutus Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Acutus Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Acutus Medical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Acutus Medical position

In addition to having Acutus Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Food Products Thematic Idea Now

Food Products
Food Products Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Food Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Food Products Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Acutus Stock

If you are still planning to invest in Acutus Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acutus Medical's history and understand the potential risks before investing.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY